This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2015 Sep 29;132(13):1218-20.

doi: 10.1161/CIRCULATIONAHA.115.018511. Epub 2015 Sep 1.

Bringing back targets to "IMPROVE" atherosclerotic cardiovascular disease outcomes: the duel for dual goals; are two targets better than one?

Erin D Michos¹, Seth S Martin¹, Roger S Blumenthal²

Affiliations

Affiliations

¹ From Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD.
² From Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD. rblument1@jhmi.edu.

PMID: 26330413
DOI: 10.1161/CIRCULATIONAHA.115.018511

Editorial

Bringing back targets to "IMPROVE" atherosclerotic cardiovascular disease outcomes: the duel for dual goals; are two targets better than one?

Erin D Michos et al. Circulation. 2015.

. 2015 Sep 29;132(13):1218-20.

doi: 10.1161/CIRCULATIONAHA.115.018511. Epub 2015 Sep 1.

Authors

Erin D Michos¹, Seth S Martin¹, Roger S Blumenthal²

Affiliations

¹ From Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD.
² From Ciccarone Center for the Prevention of Heart Disease, Johns Hopkins University School of Medicine, Baltimore, MD. rblument1@jhmi.edu.

PMID: 26330413
DOI: 10.1161/CIRCULATIONAHA.115.018511

No abstract available

Keywords: Editorials; inflammation; lipids; risk assessment.

PubMed Disclaimer

Comment in

Letter by Robinson Regarding Articles, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?" and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
Robinson JG. Robinson JG. Circulation. 2016 Mar 29;133(13):e461. doi: 10.1161/CIRCULATIONAHA.115.019345. Circulation. 2016. PMID: 27022048 No abstract available.
Response to the Letter Regarding Article, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?".
Michos ED, Martin SS, Blumenthal RS. Michos ED, et al. Circulation. 2016 Mar 29;133(13):e462. doi: 10.1161/CIRCULATIONAHA.115.020948. Circulation. 2016. PMID: 27022049 No abstract available.

Comment on

Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tershakovec AM, Blazing MA, Braunwald E. Bohula EA, et al. Circulation. 2015 Sep 29;132(13):1224-33. doi: 10.1161/CIRCULATIONAHA.115.018381. Epub 2015 Sep 1. Circulation. 2015. PMID: 26330412 Clinical Trial.

Similar articles

Response to the Letter Regarding Article, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?".
Michos ED, Martin SS, Blumenthal RS. Michos ED, et al. Circulation. 2016 Mar 29;133(13):e462. doi: 10.1161/CIRCULATIONAHA.115.020948. Circulation. 2016. PMID: 27022049 No abstract available.
Letter by Robinson Regarding Articles, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?" and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
Robinson JG. Robinson JG. Circulation. 2016 Mar 29;133(13):e461. doi: 10.1161/CIRCULATIONAHA.115.019345. Circulation. 2016. PMID: 27022048 No abstract available.
Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White J, Tershakovec AM, Blazing MA, Braunwald E. Bohula EA, et al. Circulation. 2016 Mar 29;133(13):e463. doi: 10.1161/CIRCULATIONAHA.116.020947. Circulation. 2016. PMID: 27022050 No abstract available.
IMPROVE-IT: what have we learned?
Banach M, Nikolic D, Rizzo M, Toth PP. Banach M, et al. Curr Opin Cardiol. 2016 Jul;31(4):426-33. doi: 10.1097/HCO.0000000000000305. Curr Opin Cardiol. 2016. PMID: 27218683 Review.
[The effect of a simvastatin and ezetimib combination on blood lipids and cardiovascular events in diabetic patients (comments on the subanalysis results within the IMPROVE-IT study)].
Soška V. Soška V. Vnitr Lek. 2015 Nov;61(11):965-9. Vnitr Lek. 2015. PMID: 26652785 Review. Czech.

See all similar articles

Cited by

The Use of Blood Biomarkers in Precision Medicine for the Primary Prevention of Atherosclerotic Cardiovascular Disease: a Review.
Sweeney T, Quispe R, Das T, Juraschek SP, Martin SS, Michos ED. Sweeney T, et al. Expert Rev Precis Med Drug Dev. 2021;6(4):247-258. doi: 10.1080/23808993.2021.1930531. Epub 2021 May 26. Expert Rev Precis Med Drug Dev. 2021. PMID: 34423130 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information